Mubadala

Tracked participation in 4 Atlas companies, with 0 explicitly attributed leads.

4portfolio companies

5round participations

0lead positions

nulllatest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—null → null1 roundParticipant—

ITIambic TherapeuticsScienceIambic Therapeutics develops AI-native small-molecule medicines by combining (1) physics-informed neural models for…$8.4Mvaluation$258.5MraisedRecent roundsOversubscribed financing (round size disclosed as “over $100 million”) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +16Series A · Jul 2021$53M · led by Catalio Capital Management, CoatueSeries Seed · Apr 2020$2.5M · Freeflow Ventures, Nexus Venture PartnersIambic Therapeutics—Nov 2025 → Nov 20251 roundParticipant—

CCrusoeNeocloudsCrusoe is an energy-first AI infrastructure company that builds and operates AI data center “factory” capacity and…$10Bvaluation$3.8BraisedRecent roundsSeries E (initial closing) · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersCredit facility (debt) · Aug 2025$175M · led by Victory Park CapitalCredit facility (debt) · Jun 2025$750M · led by Brookfield Asset Management (infrastructure debt platform)Crusoe$2.8BDec 2024 → Dec 20241 roundParticipant—

RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)Recursion—Oct 2017 → Sep 20202 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

nullOOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinTotal disclosed (company press kit aggregate)$304.1M—Participant

Source ↗

Nov 10, 2025ITIambic TherapeuticsScienceIambic Therapeutics develops AI-native small-molecule medicines by combining (1) physics-informed neural models for…$8.4Mvaluation$258.5MraisedRecent roundsOversubscribed financing (round size disclosed as “over $100 million”) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +16Series A · Jul 2021$53M · led by Catalio Capital Management, CoatueSeries Seed · Apr 2020$2.5M · Freeflow Ventures, Nexus Venture PartnersIambic TherapeuticsOversubscribed financing (round size disclosed as “over $100 million”)$100M—Participant

Source ↗

Dec 12, 2024CCrusoeNeocloudsCrusoe is an energy-first AI infrastructure company that builds and operates AI data center “factory” capacity and…$10Bvaluation$3.8BraisedRecent roundsSeries E (initial closing) · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersCredit facility (debt) · Aug 2025$175M · led by Victory Park CapitalCredit facility (debt) · Jun 2025$750M · led by Brookfield Asset Management (infrastructure debt platform)CrusoeSeries D$600M$2.8BParticipant

Source ↗

Sep 09, 2020RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries D (equity financing)$239M—Participant

Source ↗+1 ↗

Oct 03, 2017RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries B$60M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Source ↗+1 ↗

Source ↗